JOHNSON & JOHNSON is 340.3x more valuable than Zymeworks Inc. by market capitalization ($573.71 B vs $1.69 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZYME | JNJ |
|---|---|---|
| Market cap | $1.69 B | $573.71 B |
| US-listed rank | #2236 | #20 |
| Revenue (latest FY) | $105.97M | $94.19B |
| Net income (latest FY) | -$81.13M | $26.80B |
| Net margin | -76.6% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 324 | 984 |
JOHNSON & JOHNSON is 340.3x more valuable than Zymeworks Inc. by market capitalization ($573.71 B vs $1.69 B).
In their latest fiscal years, Zymeworks Inc. reported $105.97M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Zymeworks Inc. and JOHNSON & JOHNSON, or browse the full rankings.